Targets › ALOX5
7 programs from 7 companies in 7 trials: 5 Phase 2, 2 Phase 1; Oncology, Other, Immunology; next expected readout Dec 2026.
Catalyzes the oxygenation of arachidonate ((5Z,8Z,11Z,14Z)-eicosatetraenoate) to 5-hydroperoxyeicosatetraenoate (5-HPETE) followed by the dehydration to 5,6- epoxyeicosatetraenoate (Leukotriene A4/LTA4), the first two steps in the biosynthesis of leukotrienes, which are potent mediators of inflammation. Also catalyzes the oxygenation of arachidonate into 8-hydroperoxyicosatetraenoate (8-HPETE) and…. (UniProt, P09917)
Open in Phaseline: the race on ALOX5, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Massachusetts General Hospital | Omega 3 (EPA-enriched) Pro-resolving lipid mediator precursor; substrate for production of specialized pro-resolv | PTGS1, PTGS2, ALOX5 | Phase 2 | Treatment Resistant Depression | Mar 2027 |
| AHS Cancer Control Alberta | Mesalamine Arachidonate 5-lipoxygenase inhibitor; Peroxisome proliferator-activated receptor gamma agonist; Cyclooxygenase inhibitor | ALOX5, PPARG, PTGS2, PTGS1 | Phase 2 | Immune-related Adverse Event | Aug 2027 |
| NYU Langone Health | Sulfasalazine Arachidonate 5-lipoxygenase inhibitor; Cyclooxygenase inhibitor | ALOX5, PTGS2, PTGS1 | Phase 2 | Rheumatic Disease | Jan 2028 |
| Rutgers, The State University of New Jersey | Sulfasalazine Arachidonate 5-lipoxygenase inhibitor; Cyclooxygenase inhibitor | ALOX5, PTGS2, PTGS1 | Phase 2 | Preterm Birth | Jan 2028 |
| Ann-Sofie Backman | Mesalamine Arachidonate 5-lipoxygenase inhibitor; Peroxisome proliferator-activated receptor gamma agonist; Cyclooxygenase inhibitor | ALOX5, PPARG, PTGS2, PTGS1 | Phase 2 | Lynch Syndrome | Sep 2032 |
| University of Zurich | Sulfasalazine Arachidonate 5-lipoxygenase inhibitor; Cyclooxygenase inhibitor | ALOX5, PTGS2, PTGS1 | Phase 1 | Glioblastoma | Dec 2026 |
| Assistance Publique - Hôpitaux de Paris | Sulfasalazine Arachidonate 5-lipoxygenase inhibitor; Cyclooxygenase inhibitor | ALOX5, PTGS2, PTGS1 | Phase 1 | Acute Myeloid Leukemia | Dec 2026 |
Glioblastoma (1) Preterm Birth (1) Rheumatic Disease (1) Acute Myeloid Leukemia (1) Treatment Resistant Depression (1) Lynch Syndrome (1) Immune-related Adverse Event (1)
small molecule (6), mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.